These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 35568835)

  • 21. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
    Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
    J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
    Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining breast cancer intrinsic subtypes by quantitative receptor expression.
    Cheang MC; Martin M; Nielsen TO; Prat A; Voduc D; Rodriguez-Lescure A; Ruiz A; Chia S; Shepherd L; Ruiz-Borrego M; Calvo L; Alba E; Carrasco E; Caballero R; Tu D; Pritchard KI; Levine MN; Bramwell VH; Parker J; Bernard PS; Ellis MJ; Perou CM; Di Leo A; Carey LA
    Oncologist; 2015 May; 20(5):474-82. PubMed ID: 25908555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
    Prat A; Chaudhury A; Solovieff N; Paré L; Martinez D; Chic N; Martínez-Sáez O; Brasó-Maristany F; Lteif A; Taran T; Babbar N; Su F
    J Clin Oncol; 2021 May; 39(13):1458-1467. PubMed ID: 33769862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
    Schettini F; Nucera S; Brasó-Maristany F; De Santo I; Pascual T; Bergamino M; Galván P; Conte B; Seguí E; García Fructuoso I; Gómez Bravo R; Rivera P; Rodríguez AB; Martínez-Sáez O; Ganau S; Sanfeliu E; González-Farre B; Vidal Losada MJ; Adamo B; Cebrecos I; Mension E; Oses G; Jares P; Vidal-Sicart S; Mollà M; Muñoz M; Prat A
    ESMO Open; 2024 Jul; 9(7):103619. PubMed ID: 38943737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance.
    Sali AP; Sharma N; Verma A; Beke A; Shet T; Patil A; Pai T; Nair N; Parmar V; Gupta S; Hawaldar R; Desai SB
    Clin Breast Cancer; 2020 Oct; 20(5):382-389. PubMed ID: 32467058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
    Jaber MI; Song B; Taylor C; Vaske CJ; Benz SC; Rabizadeh S; Soon-Shiong P; Szeto CW
    Breast Cancer Res; 2020 Jan; 22(1):12. PubMed ID: 31992350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
    Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
    Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
    Kelly CM; Bernard PS; Krishnamurthy S; Wang B; Ebbert MT; Bastien RR; Boucher KM; Young E; Iwamoto T; Pusztai L
    Oncologist; 2012; 17(4):492-8. PubMed ID: 22418568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    Troester MA; Sun X; Allott EH; Geradts J; Cohen SM; Tse CK; Kirk EL; Thorne LB; Mathews M; Li Y; Hu Z; Robinson WR; Hoadley KA; Olopade OI; Reeder-Hayes KE; Earp HS; Olshan AF; Carey LA; Perou CM
    J Natl Cancer Inst; 2018 Feb; 110(2):176-82. PubMed ID: 28859290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.
    Liu FF; Shi W; Done SJ; Miller N; Pintilie M; Voduc D; Nielsen TO; Nofech-Mozes S; Chang MC; Whelan TJ; Weir LM; Olivotto IA; McCready DR; Fyles AW
    J Clin Oncol; 2015 Jun; 33(18):2035-40. PubMed ID: 25964246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
    BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
    Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
    Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
    Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
    Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
    Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.